Spero Therapeutics Inc (SPRO)
1.25
-0.06
(-4.58%)
USD |
NASDAQ |
Nov 14, 16:00
1.28
+0.03
(+2.40%)
After-Hours: 07:45
Spero Therapeutics Cash from Operations (Quarterly): -18.74M for June 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -18.74M |
| March 31, 2024 | 5.938M |
| December 31, 2023 | -17.49M |
| September 30, 2023 | 15.92M |
| June 30, 2023 | -18.56M |
| March 31, 2023 | -12.85M |
| December 31, 2022 | 44.48M |
| September 30, 2022 | -0.957M |
| June 30, 2022 | -23.03M |
| March 31, 2022 | -28.22M |
| December 31, 2021 | -27.35M |
| September 30, 2021 | -4.952M |
| June 30, 2021 | -16.57M |
| March 31, 2021 | -15.48M |
| December 31, 2020 | -16.38M |
| Date | Value |
|---|---|
| September 30, 2020 | -21.26M |
| June 30, 2020 | -24.90M |
| March 31, 2020 | -23.33M |
| December 31, 2019 | -17.37M |
| September 30, 2019 | -9.659M |
| June 30, 2019 | -12.07M |
| March 31, 2019 | -10.92M |
| December 31, 2018 | -13.51M |
| September 30, 2018 | -5.514M |
| June 30, 2018 | -8.641M |
| March 31, 2018 | -11.96M |
| December 31, 2017 | -12.74M |
| September 30, 2017 | -10.52M |
| June 30, 2017 | -8.877M |
| March 31, 2017 | -6.979M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-28.22M
Minimum
Mar 2022
44.48M
Maximum
Dec 2022
-11.64M
Average
-17.37M
Median
Dec 2019
Cash from Operations (Quarterly) Benchmarks
| Arbutus Biopharma Corp | -20.74M |
| Equillium Inc | 0.73M |
| NovaBay Pharmaceuticals Inc | -2.061M |
| Palatin Technologies Inc | -6.472M |
| iBio Inc | -4.854M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -14.38M |
| Free Cash Flow Per Share (Quarterly) | -0.3474 |
| Free Cash Flow to Equity (Quarterly) | -18.74M |
| Free Cash Flow Yield | -21.48% |